Suppr超能文献

一名具有SATB2基因最后一个外显子移码突变的患者出现骨转换增加、骨质疏松、胫骨渐进性弓形弯曲、骨折和脊柱侧弯。

Increased bone turnover, osteoporosis, progressive tibial bowing, fractures, and scoliosis in a patient with a final-exon SATB2 frameshift mutation.

作者信息

Boone Philip M, Chan Yiu Man, Hunter Jill V, Pottkotter Louis E, Davino Nelson A, Yang Yaping, Beuten Joke, Bacino Carlos A

机构信息

Department of Molecular and Human Genetics, Baylor College of Medicine.

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China.

出版信息

Am J Med Genet A. 2016 Nov;170(11):3028-3032. doi: 10.1002/ajmg.a.37847. Epub 2016 Jul 13.

Abstract

Haploinsufficiency of SATB2 causes cleft palate, intellectual disability with deficient speech, facial and dental abnormalities, and other variable features known collectively as SATB2-associated syndrome. This phenotype was accompanied by osteoporosis, fractures, and tibial bowing in two previously reported adult patients; each possessed SATB2 mutations either predicted or demonstrated to escape nonsense-mediated decay, suggesting that the additional bone defects result from a dominant negative effect and/or age-dependent penetrance. These hypotheses remain to be confirmed, as do the specific downstream defects causing bone abnormalities. We report a SATB2 mutation (c.2018dupA; p.(H673fs)) in a 15-year-old patient whose SATB2-associated syndrome phenotype is accompanied by osteoporosis, fractures, progressive tibial bowing, and scoliosis. As this homeodomain-disrupting and predicted truncating mutation resides within the final exon of SATB2, escape from nonsense-mediated decay is likely. Thus, we provide further evidence of bone phenotypes beyond those typically associated with SATB2-associated syndrome in individuals with potential dominant-negative SATB2 alleles, as well as evidence for age-dependence of bone features. Elevations in alkaline phosphatase, urinary N-telopeptide/creatinine ratio, and osteocalcin in the patient indicate increased bone turnover. We propose surveillance and treatment with osteoclast inhibitors to prevent fractures and to slow progressive bone deformities. © 2016 Wiley Periodicals, Inc.

摘要

SATB2单倍剂量不足会导致腭裂、伴有语言缺陷的智力障碍、面部和牙齿异常以及其他统称为SATB2相关综合征的可变特征。在之前报道的两名成年患者中,这种表型伴有骨质疏松、骨折和胫骨弯曲;两人都携带预测或已证实可逃避无义介导衰变的SATB2突变,这表明额外的骨骼缺陷是由显性负效应和/或年龄依赖性外显率导致的。这些假设以及导致骨骼异常的具体下游缺陷仍有待证实。我们报告了一名15岁患者的SATB2突变(c.2018dupA;p.(H673fs)),其SATB2相关综合征表型伴有骨质疏松、骨折、进行性胫骨弯曲和脊柱侧凸。由于这个破坏同源结构域且预测会导致截短的突变位于SATB2的最后一个外显子内,很可能逃避了无义介导的衰变。因此,我们提供了进一步的证据,表明在具有潜在显性负性SATB2等位基因的个体中,骨骼表型超出了通常与SATB2相关综合征相关的范围,同时也提供了骨骼特征具有年龄依赖性的证据。患者碱性磷酸酶、尿N-端肽/肌酐比值和骨钙素升高表明骨转换增加。我们建议使用破骨细胞抑制剂进行监测和治疗,以预防骨折并减缓进行性骨骼畸形。© 2016威利期刊公司

相似文献

2
Genotype and phenotype in 12 additional individuals with SATB2-associated syndrome.
Clin Genet. 2017 Oct;92(4):423-429. doi: 10.1111/cge.12982. Epub 2017 Mar 7.
3
SATB2-associated syndrome in patients from Japan: Linguistic profiles.
Am J Med Genet A. 2019 Jun;179(6):896-899. doi: 10.1002/ajmg.a.61114. Epub 2019 Mar 7.
4
Intragenic duplication--a novel causative mechanism for SATB2-associated syndrome.
Am J Med Genet A. 2014 Dec;164A(12):3083-7. doi: 10.1002/ajmg.a.36769. Epub 2014 Sep 23.
6
SATB2-associated syndrome: Mechanisms, phenotype, and practical recommendations.
Am J Med Genet A. 2017 Feb;173(2):327-337. doi: 10.1002/ajmg.a.38022. Epub 2016 Oct 24.
7
Bone health and SATB2-associated syndrome.
Clin Genet. 2018 Mar;93(3):588-594. doi: 10.1111/cge.13121. Epub 2017 Dec 27.
8
Further supporting evidence for the SATB2-associated syndrome found through whole exome sequencing.
Am J Med Genet A. 2015 May;167A(5):1026-32. doi: 10.1002/ajmg.a.36849.
10
Patients with SATB2-associated syndrome exhibiting multiple odontomas.
Am J Med Genet A. 2018 Dec;176(12):2614-2622. doi: 10.1002/ajmg.a.40670. Epub 2018 Dec 21.

引用本文的文献

1
SATB2 promotes humeral fracture healing in rats by activating the PI3K/AKT pathway.
Open Life Sci. 2025 Aug 8;20(1):20251126. doi: 10.1515/biol-2025-1126. eCollection 2025.
2
Quantitative Phenotype Morbidity Description of -Associated Syndrome.
Hum Mutat. 2023 Apr 26;2023:8200176. doi: 10.1155/2023/8200176. eCollection 2023.
3
The skeletal abnormalities and their clinical challenges in -associated syndrome.
JBMR Plus. 2025 Feb 5;9(4):ziaf023. doi: 10.1093/jbmrpl/ziaf023. eCollection 2025 Apr.
4
Proteome-scale prediction of molecular mechanisms underlying dominant genetic diseases.
PLoS One. 2024 Aug 22;19(8):e0307312. doi: 10.1371/journal.pone.0307312. eCollection 2024.
5
Genetic analysis of a child with ‑associated syndrome and literature study.
Exp Ther Med. 2023 Jun 20;26(2):372. doi: 10.3892/etm.2023.12071. eCollection 2023 Aug.
8
-associated syndrome caused by a novel mutation in a Chinese boy: A case report and literature review.
World J Clin Cases. 2021 Jul 26;9(21):6081-6090. doi: 10.12998/wjcc.v9.i21.6081.
10
Satb2 regulates proliferation and nuclear integrity of pre-osteoblasts.
Bone. 2019 Oct;127:488-498. doi: 10.1016/j.bone.2019.07.017. Epub 2019 Jul 17.

本文引用的文献

1
Severe hypercalcemia following denosumab treatment in a juvenile patient.
J Bone Miner Metab. 2016 Jan;34(1):118-22. doi: 10.1007/s00774-015-0677-z. Epub 2015 Jun 9.
2
Further supporting evidence for the SATB2-associated syndrome found through whole exome sequencing.
Am J Med Genet A. 2015 May;167A(5):1026-32. doi: 10.1002/ajmg.a.36849.
3
Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Pediatr Blood Cancer. 2015 Jun;62(6):1078-80. doi: 10.1002/pbc.25393. Epub 2015 Jan 3.
4
Intragenic duplication--a novel causative mechanism for SATB2-associated syndrome.
Am J Med Genet A. 2014 Dec;164A(12):3083-7. doi: 10.1002/ajmg.a.36769. Epub 2014 Sep 23.
5
The role of SATB2 in skeletogenesis and human disease.
Cytokine Growth Factor Rev. 2014 Feb;25(1):35-44. doi: 10.1016/j.cytogfr.2013.12.010. Epub 2013 Dec 25.
6
Further delineation of the SATB2 phenotype.
Eur J Hum Genet. 2014 Aug;22(8):1034-9. doi: 10.1038/ejhg.2013.280. Epub 2013 Dec 4.
7
Disorders with similar clinical phenotypes reveal underlying genetic interaction: SATB2 acts as an activator of the UPF3B gene.
Hum Genet. 2013 Dec;132(12):1383-93. doi: 10.1007/s00439-013-1345-9. Epub 2013 Aug 8.
8
Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease.
J Clin Endocrinol Metab. 2013 Aug;98(8):3121-6. doi: 10.1210/jc.2013-1143. Epub 2013 Jun 20.
9
Denosumab treatment for fibrous dysplasia.
J Bone Miner Res. 2012 Jul;27(7):1462-70. doi: 10.1002/jbmr.1603.
10
Case series: 2q33.1 microdeletion syndrome--further delineation of the phenotype.
J Med Genet. 2011 May;48(5):290-8. doi: 10.1136/jmg.2010.084491. Epub 2011 Feb 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验